

Anti-CACYBP Antibody

Catalog # ABO12780

Product Information

Application	WB, IHC-P
Primary Accession	Q9HB71
Host	Rabbit
Reactivity	Human, Mouse, Rat
Clonality	Polyclonal
Format	Lyophilized
Description	Rabbit IgG polyclonal antibody for Calcyclin-binding protein(CACYBP) detection. Tested with WB, IHC-P in Human;Mouse;Rat.
Reconstitution	Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

Additional Information

Gene ID	27101
Other Names	Calcyclin-binding protein, CacyBP, hCacyBP, S100A6-binding protein, Siah-interacting protein, CACYBP, S100A6BP, SIP
Calculated MW	26210
Application Details	Immunohistochemistry(Paraffin-embedded Section), 0.5-1 μ g/ml, Human, Mouse, Rat, By Heat Western blot, 0.1-0.5 μ g/ml, Human, Mouse, Rat
Subcellular Localization	Nucleus . Cytoplasm . Cytoplasmic at low calcium concentrations. In neuroblastoma cells, after a retinoic acid (RA) induction and calcium increase, it localizes in both the nucleus and cytoplasm. The nuclear fraction may be phosphorylated.
Source	Eukaryota
Protein Name	Calcyclin-binding protein
Contents	Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na ₂ HPO ₄ , 0.05mg Na ₃ N.
Immunogen	A synthetic peptide corresponding to a sequence at the N-terminus of human CACYBP (7-47aa QKDLEEVKVLLEKATRKRVRDALTAEKSKIETEIKNKMQQK), different from the related mouse sequence by five amino acids, and from the related rat sequence by six amino acids.
Purification	Immunogen affinity purified.

Cross Reactivity

No cross reactivity with other proteins

Storage

At -20 °C for one year. After reconstitution, at 4 °C for one month. It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.

Protein Information

Name

CACYBP

Synonyms

S100A6BP, SIP

Function

May be involved in calcium-dependent ubiquitination and subsequent proteasomal degradation of target proteins. Probably serves as a molecular bridge in ubiquitin E3 complexes. Participates in the ubiquitin-mediated degradation of beta-catenin (CTNNB1).

Cellular Location

Nucleus. Cytoplasm. Note=Cytoplasmic at low calcium concentrations. In neuroblastoma cells, after a retinoic acid (RA) induction and calcium increase, it localizes in both the nucleus and cytoplasm. The nuclear fraction may be phosphorylated


Background

Calcyclin-binding protein is a protein that in humans is encoded by the CACYBP gene. And this gene is mapped to 1q24-q25. The protein encoded by this gene is a calcyclin binding protein. It may be involved in calcium-dependent ubiquitination and subsequent proteasomal degradation of target proteins. In addition, it probably serves as a molecular bridge in ubiquitin E3 complexes and participates in the ubiquitin-mediated degradation of beta-catenin. Two alternatively spliced transcript variants encoding different isoforms have been found for this gene.


Images




Western blot analysis of CACYBP expression in rat brain extract (lane 1), mouse testis extract (lane 2) and SW620 whole cell lysates (lane 3). CACYBP at 26KD was detected using rabbit anti-CACYBP Antigen Affinity purified polyclonal antibody (Catalog # ABO12780) at 0.5 µg/mL. The blot was developed using chemiluminescence (ECL) method .



CACYBP was detected in paraffin-embedded sections of mouse testis tissues using rabbit anti- CACYBP Antigen Affinity purified polyclonal antibody (Catalog # ABO12780) at 1 µg/mL. The immunohistochemical section was developed using SABC method .



CACYBP was detected in paraffin-embedded sections of rat testis tissues using rabbit anti- CACYBP Antigen Affinity purified polyclonal antibody (Catalog # ABO12780) at 1 μ g/mL. The immunohistochemical section was developed using SABC method .



CACYBP was detected in paraffin-embedded sections of human intestinal cancer tissues using rabbit anti- CACYBP Antigen Affinity purified polyclonal antibody (Catalog # ABO12780) at 1 μ g/mL. The immunohistochemical section was developed using SABC method .

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.